ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

China to use BioNTech vaccine as booster shot, sources say

Joint venture with Fosun Pharma to make 100m to 200m vaccines a month

Fosun Pharma’s joint venture in Shanghai with Germany's BioNTech is expected to reach an annual production capacity of 1 billion doses of COVID-19 vaccine by the end of the year.   © Reuters

Chinese drug regulators completed an expert panel review of a COVID-19 mRNA vaccine co-developed by Fosun Pharma and Germany's BioNTech, and now the shot is in the administrative review stage, according to Fosun.

The Shanghai-based pharmaceutical company is sticking with its previously announced plan to start domestic trial production by the end of August, Fosun Chairman Wu Yifang said Wednesday at a shareholders meeting.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more